Please assess the completion status of the following clinical trial:

Trial Title: AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Hematologic Malignances Arm~* Patients must have CLL, prolymphocytic leukemia, or lymphoma (Hodgkins or Non-Hodgkins) as defined by 2008 WHO criteria or multiple myeloma as defined by IMWG criteria~* Patients must have received at least one prior antineoplastic therapy, must have progressed after at least 1 prior therapy, and for whom no standard therapy is available or whom decline such options; prior autologous and/or allogeneic transplant is permitted~* Prior biologic therapy or prior radiation is permitted; however, at least 28 days must have elapsed since the completion of prior therapy and patients must have recovered from all therapy-associated toxicities to no greater than grade 1 at the time of registration~* Patients with symptomatic disease may receive palliative corticosteroids up to 1 week before initiating therapy~* Patients must be off any prior chemotherapy for at least 28 days or 3 half lives, whichever is longer, and all therapy-related toxicity must have resolved to grade 1 or less~* ANC \>= 1000/uL~* Total bilirubin \< 1.5 mg/dL~* Serum creatinine =\< 1.5x institutional upper limit of normal or estimated creatinine clearance \>= 50 ml/min by MDRD (original or abbreviated), or measured creatinine clearance \>= 50 mL/min~* ECOG/WHO performance score of 0-1~* Patients must be able to swallow capsules~* Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial~* Women with potential for child bearing must have a negative pregnancy test at screening; both men and women are required to use appropriate contraception during study~* Platelet count \>= 50,000/uL~* AST and ALT =\< 5x the institutional upper limit of normal Inclusion Solid Tumors Arm~* Histologically or cytologically confirmed advanced or recurrent solid tumor malignancy.~* Chemotherapy: up to three prior cytotoxic chemotherapy treatments.~* Radiation Therapy: prior radiation therapy allowed.~* Surgery: Prior curative and palliative intent surgery is allowed.~* Age ≥ 18 years~* ECOG performance status 0-1~* Life expectancy of greater than 12 weeks.~* Patients must have normal organ and marrow function as defined below:~* Leukocytes ≥ 3,000/mcL~* Absolute neutrophil count ≥ 1,500/mcL~* Platelets ≥ 100,000/mcL~* Total bilirubin \< 1.5 mg/dL~* AST(SGOT)/ALT(SGPT) ≤ 2.5 x institutional upper limit of normal (ULN); ≤ 5 x ULN in presence of liver metastasis~* Creatinine ≤ 1.5 x ULN OR Creatinine clearance ≥ 50 mL/min by MDRD (original or abbreviated), or measured creatinine clearance ≥ 50 ml/min~* Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial~* Women with potential for child bearing must have a negative pregnancy test at screening; both men and women are required to use appropriate contraception during study~Exclusion Hematologic Malignances Arm~* Pregnant women are excluded from this study~* Patients with malabsorption or any other condition that in the opinion of the principal investigator could cause difficulty in absorption of drug~* Breastfeeding should be discontinued if the mother is treated with AR-42~* Patients with malignant cells in the cerebrospinal fluid or parenchyma within the preceding 3 months or patients with primary CNS lymphoma are not eligible~* Patients with uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP) are not eligible~* Patients receiving concurrent corticosteroids less than 1 week prior to protocol therapy other than for physiologic maintenance treatment or control of AIHA or ITP~* Concurrent use of complementary or alternative medicines that in the opinion of the principal investigator would confound the interpretation of toxicities and/or antitumor activity of the study drug~* Patients with a currently active second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, increase patient risk, shorten survival to \< 1 year, or confound data interpretation~* Patients with a mean QTcB \> 450 msec in males and \> 470 msec in females~* Patients who are receiving concurrent antineoplastic therapy~* Any other medical condition, including mental illness or substance abuse, deemed by the principal investigator to likely interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results~* Patients with significant cardiovascular disease, including a myocardial infarction or unstable angina within 6 months or unstable cardiac arrhythmias are not eligible for the study~* Known HIV infection~Exclusion Solid Tumors Arm~* Pregnant women are excluded from this study~* Patients with malabsorption or any other condition that in the opinion of the principal investigator could cause difficulty in absorption of drug~* Patients with malignant cells in the cerebrospinal fluid or parenchyma within the preceding 3 months or patients with primary CNS lymphoma are not eligible~* Patients with uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP) are not eligible~* Patients receiving concurrent corticosteroids less than 1 week prior to protocol therapy other than for physiologic maintenance treatment or control of AIHA or ITP~* Concurrent use of complementary or alternative medicines that in the opinion of the principal investigator would confound the interpretation of toxicities and/or antitumor activity of the study drug~* Concurrent use of complementary or alternative medicines that in the opinion of the principal investigator would confound the interpretation of toxicities and/or antitumor activity of the study drug~* Patients with a currently active second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, increase patient risk, shorten survival to \< 1 year, or confound data interpretation.~* Patients with a mean QTcB \> 450 msec in males and \> 470 msec in females~* Patients who are receiving concurrent antineoplastic therapy.~* Any other medical condition, including mental illness or substance abuse, deemed by the principal investigator to likely interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.~* Patients with significant cardiovascular disease, including a myocardial infarction or unstable angina within 6 months or unstable cardiac arrhythmias are not eligible for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Hematologic Malignancies) (Type: EXPERIMENTAL): Patients will receive orally administered AR-42 three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
- Arm II (Solid Tumors) (Type: EXPERIMENTAL): Patients will receive orally administered AR-42 three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).

Based on this trial design, predict the completion outcome and termination type (if applicable).